HUE056408T2 - Kombinációk és alkalmazásaik - Google Patents

Kombinációk és alkalmazásaik

Info

Publication number
HUE056408T2
HUE056408T2 HUE16756997A HUE16756997A HUE056408T2 HU E056408 T2 HUE056408 T2 HU E056408T2 HU E16756997 A HUE16756997 A HU E16756997A HU E16756997 A HUE16756997 A HU E16756997A HU E056408 T2 HUE056408 T2 HU E056408T2
Authority
HU
Hungary
Prior art keywords
combinations
applications
Prior art date
Application number
HUE16756997A
Other languages
English (en)
Hungarian (hu)
Inventor
Jan Endell
Mark Winderlich
Rainer Boxhammer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of HUE056408T2 publication Critical patent/HUE056408T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
HUE16756997A 2015-08-21 2016-08-18 Kombinációk és alkalmazásaik HUE056408T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15181925 2015-08-21

Publications (1)

Publication Number Publication Date
HUE056408T2 true HUE056408T2 (hu) 2022-02-28

Family

ID=54010888

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16756997A HUE056408T2 (hu) 2015-08-21 2016-08-18 Kombinációk és alkalmazásaik

Country Status (23)

Country Link
US (3) US11224654B2 (enExample)
EP (2) EP3954388A1 (enExample)
JP (4) JP6862422B2 (enExample)
KR (2) KR102786010B1 (enExample)
CN (2) CN107921129B (enExample)
AU (3) AU2016311136B2 (enExample)
CA (1) CA2995738A1 (enExample)
CY (1) CY1124706T1 (enExample)
DK (1) DK3337506T3 (enExample)
ES (1) ES2891336T3 (enExample)
HR (1) HRP20211291T1 (enExample)
HU (1) HUE056408T2 (enExample)
IL (2) IL257345B2 (enExample)
LT (1) LT3337506T (enExample)
MX (2) MX392561B (enExample)
PL (1) PL3337506T3 (enExample)
PT (1) PT3337506T (enExample)
RS (1) RS62260B1 (enExample)
RU (1) RU2767063C2 (enExample)
SI (1) SI3337506T1 (enExample)
SM (1) SMT202100541T1 (enExample)
WO (1) WO2017032679A1 (enExample)
ZA (1) ZA201801052B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) * 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
PL3630177T3 (pl) 2017-05-31 2024-04-08 Morphosys Ag Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2022005032A (es) * 2019-10-31 2022-07-27 Morphosys Ag Terapia secuencial anti cumulo de diferenciacion 19 (cd19).
CA3203587A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
KR20240131370A (ko) * 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
SI3029041T1 (sl) 2000-04-25 2020-08-31 Icos Corporation Inhibitorji humane delta fosfatidil-inozitol 3-kinaze
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2662340C (en) 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
AU2010311559B2 (en) * 2009-10-27 2016-07-07 Amgen Research (Munich) Gmbh Dosage regimen for administering a CD19xCD3 bispecific antibody
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
TWI545134B (zh) * 2010-10-22 2016-08-11 西雅圖遺傳學公司 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
SI2744515T1 (sl) * 2011-08-16 2022-05-31 Morphosys Ag Kombinirana terapija s protitelesom proti CD19 in dušikovim iperitom
AU2012296905B2 (en) 2011-08-16 2017-01-05 Incyte Corporation Combination therapy with an anti - CD19 antibody and a purine analog
EA201691327A1 (ru) 2012-03-05 2017-03-31 Джилид Калистога Ллс Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
HRP20181367T4 (hr) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. Liječenje raka korištenjem modulatora izoforme pi3 kinaze
CA2900658A1 (en) 2013-02-15 2014-08-21 3M Innovative Properties Company System and method for making pleated filter media
CA2951427A1 (en) 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
CA2986175A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2016311136B2 (en) * 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
MA45124B1 (fr) 2016-05-30 2021-05-31 Morphosys Ag Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
CN115998859A (zh) 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
PL3630177T3 (pl) 2017-05-31 2024-04-08 Morphosys Ag Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2021013101A (es) 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
IL317199A (en) 2019-10-31 2025-01-01 Morphosys Ag Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
MX2022005032A (es) 2019-10-31 2022-07-27 Morphosys Ag Terapia secuencial anti cumulo de diferenciacion 19 (cd19).
CN115956088A (zh) 2020-06-22 2023-04-11 莫佛塞斯公司 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
CA3203587A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
KR20240131370A (ko) 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임

Also Published As

Publication number Publication date
CN107921129B (zh) 2022-05-27
AU2016311136B2 (en) 2022-02-17
CN107921129A (zh) 2018-04-17
IL257345B2 (en) 2023-03-01
IL297057B1 (en) 2025-07-01
US20220088197A1 (en) 2022-03-24
AU2022202800B2 (en) 2024-01-04
CN115054697B (zh) 2024-06-11
DK3337506T3 (da) 2021-09-06
BR112018003263A2 (pt) 2018-09-25
US20180228893A1 (en) 2018-08-16
ZA201801052B (en) 2021-05-26
US11224654B2 (en) 2022-01-18
EP3337506A1 (en) 2018-06-27
JP2023093495A (ja) 2023-07-04
RS62260B1 (sr) 2021-09-30
KR20240052084A (ko) 2024-04-22
IL297057B2 (en) 2025-11-01
EP3337506B1 (en) 2021-07-21
CY1124706T1 (el) 2022-07-22
MX392561B (es) 2025-03-24
US20250195646A1 (en) 2025-06-19
JP6862422B2 (ja) 2021-04-21
CA2995738A1 (en) 2017-03-02
JP2025131697A (ja) 2025-09-09
MX2022006154A (es) 2022-10-07
ES2891336T3 (es) 2022-01-27
KR20180042335A (ko) 2018-04-25
IL297057A (en) 2022-12-01
EP3954388A1 (en) 2022-02-16
PL3337506T3 (pl) 2022-01-03
AU2024202109A1 (en) 2024-05-02
HK1247122A1 (zh) 2018-09-21
IL257345A (en) 2018-03-29
RU2767063C2 (ru) 2022-03-16
IL257345B (en) 2022-11-01
NZ739706A (en) 2025-02-28
AU2022202800A1 (en) 2022-05-19
MX2018002241A (es) 2018-03-23
KR102786010B1 (ko) 2025-03-26
LT3337506T (lt) 2021-10-11
WO2017032679A1 (en) 2017-03-02
PT3337506T (pt) 2021-09-24
AU2016311136A1 (en) 2018-03-01
JP2021113194A (ja) 2021-08-05
SMT202100541T1 (it) 2021-11-12
JP2018523685A (ja) 2018-08-23
RU2018107929A (ru) 2019-09-23
CN115054697A (zh) 2022-09-16
US12194095B2 (en) 2025-01-14
RU2018107929A3 (enExample) 2020-01-14
SI3337506T1 (sl) 2021-12-31
HRP20211291T1 (hr) 2021-12-10

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL293377A (en) Hsd17b13 variants and uses thereof
HUE047255T2 (hu) Syntac polipeptidek és alkalmazásaik
HUE046621T2 (hu) Promóter szekvencia és alkalmazásai
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE067016T2 (hu) Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
HUE043060T2 (hu) Triazolopirimidin-vegyületek és alkalmazásaik
HUE054339T2 (hu) CD73-ra specifikus kötõmolekulák és alkalmazásaik
HUE048791T2 (hu) CD123 kötõszerek és alkalmazásaik
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
HUE054159T2 (hu) HPK1 gátlók és azok alkalmazási módja
EP3411412A4 (en) FIT-IMMUNOGLOBULIN TECHNOLOGY AND USES THEREOF
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
HUE064791T2 (hu) APRIL ellenes antitest molekulák és alkalmazásaik
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
HUE058204T2 (hu) Riluzol prodrugok és felhasználásuk
HUE059338T2 (hu) Ellenanyagok, alkalmazások és eljárások
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
HUE055233T2 (hu) Az EGFR gátló és annak elkészítése és alkalmazása
HUE056596T2 (hu) Módosított biológiai szabályozó szer és ennek alkalmazásai
HUE054347T2 (hu) MK2 inhibitorok és azok alkalmazásai
HUE059925T2 (hu) Módosított aminoacil-tRNS-szintetáz és alkalmazása
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf